close
References
  1. Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705
  2. Campbell AP, Tokars JI, Reynolds S, et al. Influenza antiviral treatment and length of stay. Pediatrics. 2021;148(4):e2021050417.
  3. Chen JY, Wei SK, Lai CC, Weng TS, Wang HH. A meta-analysis comparing the efficacy and safety of peramivir with other neuraminidase inhibitors for influenza treatment. Medicina (Kaunas). 2020;56(2):63.
  4. Chotpitayasunondh T, Fischer TK, Heraud JM, Hurt AC, Monto AS, Osterhaus A, Shu Y, Tam JS. Influenza and COVID-19: what does co-existence mean? Influenza Other Respir Viruses. 2021;15(3):407-412.
  5. Chow EJ, Beigi RH, Riley LE, Uyeki TM. Clinical effectiveness and safety of antivirals for influenza in pregnancy. Open Forum Infect Dis. 2021;8(6):ofab138.
  6. Courtney SJ, Stromberg ZR, Kubicek-Sutherland JZ. Nucleic acid-based sensing techniques for diagnostics and surveillance of influenza.Biosensors (Basel). 2021;11(2):47.
  7. Centers for Disease Control and Prevention. FAQ Flu Season 2021-2022. Updated May 26, 2022. Accessed August 19, 2022. https://www.cdc.gov/flu/season/faq-flu-season-2021-2022.htm
  8. Centers for Disease Control and Prevention. Flu Symptoms. Updated September 21, 2021. Accessed August 19, 2022. https://www.cdc.gov/flu/symptoms/symptoms.htm
  9. Centers for Disease Control and Prevention. For Clinicians: Antiviral Medication. Updated August 16, 2022. Accessed August 19, 2022. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
  10. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
  11. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.
  12. Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320.
  13. Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2013;7 Suppl 1(Suppl 1):7-13.
  14. Jones WA, de Cassia Castro R, Masters HL III, Carrico R. Influenza management during the COVID-19 pandemic: a review of recent innovations in antiviral therapy and relevance to primary care practice, mayo clinic proceedings: innovations, quality & outcomes. Mayo Clin Proc. 2021;5(6):974-991.
  15. Centers for Disease Control and Prevention. Laboratory-Confirmed Influenza Hospitalizations. Updated August 13, 2022. Accessed August 19, 2022. https://gis.cdc.gov/grasp/fluview/fluhospchars.html
  16. Liu JW, Lin SH, Wang LC, Chiu HY, Lee JA. Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis. JAMA Netw Open. 2021;4(8):e2119151.
  17. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012;55(9):1198-1204.
  18. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis. 2018;66(10):1492-1500.
  19. Nypaver C, Dehlinger C, Carter C. Influenza and influenza vaccine: a review. J Midwifery Womens Health. 2021;66(1):45-53.
  20. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2021;31(3):e2179.
  21. Smith LE, D'Antoni D, Jain V, Pearce JM, Weinman J, Rubin GJ. A systematic review of factors affecting intended and actual adherence with antiviral medication as treatment or prophylaxis in seasonal and pandemic flu. Influenza Other Respir Viruses. 2016;10(6):462-478.
  22. Stowe J, Tessier E, Zhao H, et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. Int J Epidemiol. 2021;50(4):1124-1133.
  23. Uyeki TM. High-risk groups for influenza complications. JAMA.2020;324(22):2334.